Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124I AT-01 PET/CT in Systemic Amyloidosis
NCT05235269Phase 2Completed
- Sponsor
- Attralus
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 124I-evuzamitide in systemic amyloidosis, sponsored by Attralus. Started Nov 2021; status: completed.
02
Drugs
124I-evuzamitide
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT05235269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235269.